Name: Latest research reports of Anthem Biosciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Anthem Biosciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	02 Mar 2026	General Insurance	BOB Capital Markets Ltd.	369.30		372.45 (-0.85%)		Not Rated	pdf post cache	Broker Report GIC RE (NOT RATED): Management meet highlights BOB Capital Markets Ltd. Plans to grow international business in the 7-10% range, aided by expansion in low penetration markets pdf Copy Link Share on Share on Share on Share on Alert
	27 Feb 2026	Anthem Biosciences	BOB Capital Markets Ltd.	640.95	835.00	701.25 (-8.60%)	30.28	Buy	pdf post cache	Broker Report [Initiation] Anthem Biosciences (BUY): Full-spectrum CRDMO capabilities BOB Capital Markets Ltd. Being one of the few backward-integrated peptide manufacturers, gives it cost edge over China competitors in GLP pdf Copy Link Share on Share on Share on Share on Alert
	26 Feb 2026	Renaissance Global	BOB Capital Markets Ltd.	104.50		145.80 (-28.33%)		Not Rated	pdf post cache	Broker Report Renaissance Global (NOT RATED): Analyst Day Key Takeaways BOB Capital Markets Ltd. The company is shifting from a working-capital-heavy B2B model to a high-margin, brand-led D2C jewellery platform to drive profitability pdf Copy Link Share on Share on Share on Share on Alert
	26 Feb 2026	Bluestone Jewellery	BOB Capital Markets Ltd. Target	518.00	635.00	432.45 (19.78%)	22.59	Buy	pdf post cache	Broker Report Bluestone Jewellery & Lifestyle (BUY): Management Meet: Business Update & Key Insights BOB Capital Markets Ltd. Targeting scale-up to ~700 stores (~20% CAGR), backed by strong unit economics (~40% store-level ROCE) pdf Copy Link Share on Share on Share on Share on Alert
	25 Feb 2026	Goodluck	BOB Capital Markets Ltd. Target	1054.40	1788.00	1203.80 (-12.41%)	69.58	Buy	pdf post cache	Broker Report Goodluck India (BUY): Well positioned for sustainable long-term growth BOB Capital Markets Ltd. Goodluck has diversified product portfolio catering to growing sectors Auto, Infrastructure, Solar and Defence pdf Copy Link Share on Share on Share on Share on Alert
	23 Feb 2026	IDFC First Bank	BOB Capital Markets Ltd. Target	64.78	82.00	70.04 (-7.51%)	26.58	Buy	pdf post cache	Broker Report IDFC First Bank (BUY): Fraud impact manageable with forensic findings awaited BOB Capital Markets Ltd. IDFCFB flags suspected fraud at the Chandigarh branch related to Haryana government; forensic audit underway pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2026	Alkem Laboratories	BOB Capital Markets Ltd. Target	5444.00	5962.00	5402.50 (0.77%)	9.52	Hold	pdf post cache	Broker Report Alkem Labs (HOLD): Ex - US international segment performing strongly BOB Capital Markets Ltd. Sales/EBITDA/APAT reported 1.3%/2.4% and -3.4% below our estimates. EBITDA margin reported 25bps lower than estimates at 22.2% pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2026	Lupin	BOB Capital Markets Ltd. Target	2357.30	2553.00	2199.30 (7.18%)	8.30	Buy	pdf post cache	Broker Report Lupin (BUY): Multiple growth levers for multiple years BOB Capital Markets Ltd. Sales/EBITDA /APAT reported 8.2%/13.1%/25% above our estimates. EBITDA Margin reported 130 bps above our estimates pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2026	Eris Lifesciences	BOB Capital Markets Ltd. Reco Target	1351.60	1756.00	1414.40 (-4.44%)	29.92	Buy	pdf post cache	Broker Report Eris Lifesciences (BUY): Domestic and Internation growth levers remain intact BOB Capital Markets Ltd. Sales/EBITDA/APAT reported 2%/-1.5%/2.3% above our estimates. EBITDA Margin reported 110 bps below our estimates pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2026	Hindware Home Innovation	BOB Capital Markets Ltd. Reco Target	211.32	290.00	247.85 (-14.74%)	37.23	Buy	pdf post cache	Broker Report Hindware Home Innovation (BUY): Margin recovery gains traction; upgrade to BUY BOB Capital Markets Ltd. EBITDA 63.8% YoY as margin recovery offsets a modest top-line growth. Bathware sustains double-digit profitability pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	Senco Gold	BOB Capital Markets Ltd. Reco Target	298.05	411.00	352.15 (-15.36%)	37.90	Buy	pdf post cache	Broker Report Senco Gold (BUY): Execution Momentum Strengthens; Upgrade to BUY BOB Capital Markets Ltd. Revenue 50.1% YoY on festive and gold tailwinds; margin expands to 13.2% on SSG (+31%) and mix skewed toward owned stores (~65%) pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	Petronet LNG	BOB Capital Markets Ltd.	296.70	300.00	290.40 (2.17%)	Target met	Hold	pdf post cache	Broker Report Petronet LNG (HOLD): Operational performance below expectations BOB Capital Markets Ltd. Revenue and EBITDA decreased by 8.7%YoY and 3.9%YoY, on lower blended realisations offset by volume growth of 2.1%YoY, respectively pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	Indraprastha Gas	BOB Capital Markets Ltd. Reco Target	161.91	197.00	166.51 (-2.76%)	21.67	Buy	pdf post cache	Broker Report Indraprastha Gas (BUY): Revenue miss on volume weakness BOB Capital Markets Ltd. Revenue and EBITDA grew by 8.2%YoY and 29.9%YoY resp., driven by volume growth of 3.4%YoY and lower input gas cost pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	ONGC	BOB Capital Markets Ltd. Target	270.55	278.00	267.40 (1.18%)	Target met	Hold	pdf post cache	Broker Report ONGC (HOLD): Results above expectations on subsidiaries' performance BOB Capital Markets Ltd. Performance above expectations, given better-than-expected performance of refinery subsidiaries (HPCL and MRPL) pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	Hindustan Unilever	BOB Capital Markets Ltd. Reco Target	2136.90	2510.00	2305.20 (-7.30%)	17.46	Hold	pdf post cache	Broker Report Hindustan Unilever (HOLD): Broad-based growth BOB Capital Markets Ltd. HUL delivered 4% UVG with broad-based growth across categories; in line with expectations pdf Copy Link Share on Share on Share on Share on Alert
	13 Feb 2026	Cohance Lifesciences	BOB Capital Markets Ltd. Target	289.35	414.00	315.60 (-8.32%)	43.08	Buy	pdf post cache	Broker Report Cohance Lifesciences (BUY): FY27 is expected to be a growth year BOB Capital Markets Ltd. Sales/EBITDA/PAT reported 1.4%/4.3%/42.2 respectively below our estimates. EBITDA Margin was 52 bps below our estimates pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2026	Ashok Leyland	BOB Capital Markets Ltd. Reco Target	178.47	199.00	211.02 (-15.43%)	Target met	Hold	pdf post cache	Broker Report Ashok Leyland (HOLD): Healthy show, healthier valuations; downgrade to HOLD BOB Capital Markets Ltd. Strong volume-led performance; MHCV up 23% YoY & LCV by 20% YoY, raising revenue by 22% YoY, realisations muted down by 2% YoY pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2026	Mahindra & Mahindra	BOB Capital Markets Ltd. Target	3031.20	4625.00	3593.10 (-15.64%)	52.58	Buy	pdf post cache	Broker Report Mahindra & Mahindra (BUY): Healthy show driven by all major segments; maintain BUY BOB Capital Markets Ltd. Robust blended volume growth of 22% YoY, underscoring strong Auto and FES traction; blended realisations up by ~3% YoY pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2026	Indiqube Spaces	BOB Capital Markets Ltd.	156.47	272.00	182.41 (-14.22%)	73.84	Buy	pdf post cache	Broker Report Indiqube Spaces (BUY): Lower margins drive miss; fundamentals remain robust BOB Capital Markets Ltd. Reported EBITDA of Rs 2,372.7; -4.4% below our expectations as higher traded goods expenses weighed on margins pdf Copy Link Share on Share on Share on Share on Alert
	12 Feb 2026	Britannia Industries	BOB Capital Markets Ltd. Target	5787.00	6348.00	6102.00 (-5.16%)	9.69	Hold	pdf post cache	Broker Report Britannia Industries (HOLD): Strong Earnings Momentum BOB Capital Markets Ltd. Commodity environment remains supportive with QoQ softening in flour, palm oil and cocoa, aiding margin resilience pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

GIC RE (NOT RATED): Management meet highlights

[Initiation] Anthem Biosciences (BUY): Full-spectrum CRDMO capabilities

Renaissance Global (NOT RATED): Analyst Day Key Takeaways

Bluestone Jewellery & Lifestyle (BUY): Management Meet: Business Update & Key Insights

Goodluck India (BUY): Well positioned for sustainable long-term growth

IDFC First Bank (BUY): Fraud impact manageable with forensic findings awaited

Alkem Labs (HOLD): Ex - US international segment performing strongly

Lupin (BUY): Multiple growth levers for multiple years

Eris Lifesciences (BUY): Domestic and Internation growth levers remain intact

Hindware Home Innovation (BUY): Margin recovery gains traction; upgrade to BUY

Senco Gold (BUY): Execution Momentum Strengthens; Upgrade to BUY

Petronet LNG (HOLD): Operational performance below expectations

Indraprastha Gas (BUY): Revenue miss on volume weakness

ONGC (HOLD): Results above expectations on subsidiaries' performance

Hindustan Unilever (HOLD): Broad-based growth

Cohance Lifesciences (BUY): FY27 is expected to be a growth year

Ashok Leyland (HOLD): Healthy show, healthier valuations; downgrade to HOLD

Mahindra & Mahindra (BUY): Healthy show driven by all major segments; maintain BUY

Indiqube Spaces (BUY): Lower margins drive miss; fundamentals remain robust

Britannia Industries (HOLD): Strong Earnings Momentum

Advisor Screeners